Dyve Biosciences

9:00 AM - 9:15 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Dyve has developed a technology that broadly enables transdermal drug delivery. We leverage proven, safe molecules with a delivery challenge to create an efficient and uniquely compelling biotechnology value proposition: fast, de-risked development of novel pharmaceuticals in multibillion-dollar markets. We have human proof of concept data across a range of molecules and indications, have the potential to significantly expand the $30B+ transdermal drug delivery market, and have a scalable drug development and business model. We have clinical programs in gout and melasma which are proving the power and potential of the technology.

www.dyvebio.com/dyvestory

Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
acute gout therapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CEO / Co-Founder
Dyve Biosciences